Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • PCSK9

    - PMLiVE

    Novartis announces positive late-stage results for Leqvio monotherapy in atherosclerotic CVD

    Cardiovascular disease, including heart disease and stroke, is the leading cause of death globally

    - PMLiVE

    Novartis shares positive real-world data for Leqvio in atherosclerotic CVD

    LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke

    - PMLiVE

    Novartis announces delay in UK cholesterol drug study

    The delay was caused by recruitment issues during the COVID-19 pandemic

    - PMLiVE

    Novartis scores CHMP backing for cholesterol drug Leqvio

    Potential first-in-class treatment moves closer to EU approval

    - PMLiVE

    Novartis plans inclisiran trial in the UK

    Swiss pharma also officially opens new London headquarters

    - PMLiVE

    Novartis links up with NHS for speedy access to cholesterol drug inclisiran

    Collaboration will see drug offered to patients across the UK via clinical study

    - PMLiVE

    Novartis picks up inclisiran after completion of MedCo acquisition

    If approved could become blockbuster cholesterol treatment

    - PMLiVE

    Novartis acquires The Medicines Company for $9.7bn following takeover rumours

    MedCo's cholesterol lowering inclisiran main attraction in planned acquisition

    - PMLiVE

    The Medicines Company surges on rumours of Novartis takeover

    Buyers interested in company as it prepares to file CV drug inclisiran

    - PMLiVE

    TMC preps filings for inclisiran after final phase 3 trials hit the mark

    Less frequent dosing schedules could prove an advantage over rivals

    - PMLiVE

    TMC’s full data for inclisiran impresses at ESC

    Marketing applications expected before end of year

    - PMLiVE

    TMC rockets on data for twice-yearly cholesterol drug inclisiran

    Shares up 14% following announcement

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links